FDA declines to approve Allergan's Esmya
Allergan Plc said on Tuesday U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.
from Reuters: Health News https://reut.rs/2w20BIp
http://bit.ly/2zwRqiM